Allena Pharmaceuticals, Inc. (ALNA)
| Market Cap | 62.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.85M |
| Shares Out | 32.51M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $1.11 |
| Previous Close | $1.15 |
| Change ($) | -0.04 |
| Change (%) | -3.48% |
| Day's Open | 1.13 |
| Day's Range | 1.08 - 1.15 |
| Day's Volume | 782,315 |
| 52-Week Range | 1.02 - 3.39 |
NEWTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-cla...
NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyper...
NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...
-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -- -- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --
Is (ALNA) Outperforming Other Medical Stocks This Year?
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96% po...
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Concept...
NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
-- Presented Data at 53 rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in E nteric H yperoxal...
NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEWTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...
-- Extends Allena’s Cash Runway into 4Q 2021 -- -- Debt Can be Converted into Equity at a Price of $4.10 Per Share -- NEWTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASD...
NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral ...
-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –-
NEWTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...
NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...
NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...
NEWTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...
-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial -- -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346 --
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) –
Allena Pharmaceuticals: Rating This Stock A Buy
Allena Demolished: Weak Phase III And Dismal Prognosis
Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria
Topline data from URIROX-1 expected in 4Q 2019 Topline data from URIROX-1 expected in 4Q 2019
NEWTON, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral ...
Allena Pharmaceuticals drug, Reloxaliase, is in Phase 3 clinical trials for enteric hyperoxaluria (EH), a leading cause of the most common type of kidney stone.
NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
About ALNA
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients wit... [Read more...]
| Industry Biotechnology | IPO Date Nov 2, 2017 |
| CEO Louis Brenner | Employees 41 |
| Stock Exchange NASDAQ | Ticker Symbol ALNA |
Analyst Forecasts
According to 6 analysts, the average rating for ALNA stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 530.63% from the latest price.